RAPS Webcast. BRAZIL Regulatory Challenges with Drug Submissions. By Adriana Serrão Marcela Saad
|
|
- Lorena Williams
- 6 years ago
- Views:
Transcription
1 RAPS Webcast BRAZIL Regulatory Challenges with Drug Submissions By Adriana Serrão Marcela Saad February 10, 2012
2 Speakers: Adriana Serrão Regulatory Affairs & Marcela Saad President & Senior Consultant MarcM Consulting Canada
3 BRAZIL Regulatory Challenges with Drug Submissions
4 BRAZIL Regulatory Challenges with Drug Submissions ANVISA Structure
5 BRAZIL Regulatory Challenges with Drug Submissions 1976: General Health Law 6360/76 Regulation Timeline 1977: General Health Decree 79094/ : Registration requirements resolution IN 01/ : GMP RDC 16/ : National Health Council Resolution RDC 196/96 Ethics in CT 1997: Leaflet Ordinance 110/ : ANVISA creation Law 9782/99; Generic Law 9787/ : Generic registration RDC 391/ : Vitamins RDC 4/00; Herb Drug register RDC 17/00; Advertisement RDC 102/00
6 BRAZIL Regulatory Challenges with Drug Submissions Regulation Timeline 2001: Patent Review Law 10196; Generic Registration RDC 10/01 update; GMP update RDC 134/ : Biologic Registration RDC 80/02; Generic Registration update RDC 84/ : Price Control CMED Law : Innovative; Specific; Similar; Generic update; Homeopathic Drugs registration RDCs 136/03, 132/03, 133/03, 135/03, RDC 139/ : Guide for OTC (therapeutic indication) RDC 138/03 (under review) 2003: Registration update RDC 134/ : Leaflet update RDC 140/03; Labeling RDC 333/03; Pregnancy Risk RDC 1548/ : Herb Drug registration update RDC 48/03; Clinical Trial RDC 219/03
7 BRAZIL Regulatory Challenges with Drug Submissions Regulation Timeline 2005: Biologic Drugs registration update RDC 315/ : Generics RDC 16/07 update; Similar Drug registration update RDC 17/ : Registration Review Linkage IN 06/ : Priority RDC 28/08 (under review) 2008: Clinical Trial update - RDC 39/ : Patent Review RDC 45/ : Clinical Trial update RDC 41/ : Leaflet update RDC 47/ : Labeling update RD 71/ : API registration RDC 57/09
8 BRAZIL Regulatory Challenges with Drug Submissions 2010: GMP update RDC 17/10 Regulation Timeline 2010: Herb Drugs registration update RDC 14/ : API GMP RDC 29/ : Biologic Drug registration update RDC 55 (+ 4 guidelines) 2011: QC Imported Drug update RDC 10/ : Specific Drug registration update RDC 24/ : Bio exemption guideline update RDC 37/ : Biologic Drug variation RDC 49/ : Biologic Drug stability RDC 50/11
9 BRAZIL Regulatory Challenges with Drug Submissions Applicable Guidelines (in force) RE 482/02: In Vitro-In Vivo Study Correlation RE 894/03: Bioequivalence Protocol and Report RE 898/03: Bioequivalence Study Design and Statistic Detailing RE 899/03: Method Validation (under review) RE 01/05: Stability Study (under review) RE 1170/06: Bioequivalence Study IN 02/09: RE 48/09: IN 11/09: RE 31/10: Pivotal Batch Variation implementation after approval (under review) Variation automatic implementation after 60 days Pharmaceutical Equivalence and Dissolution Profile Note: Reference Drugs and Biologic Drugs guidelines being re-written
10 BRAZIL Regulatory Challenges with Drug Submissions Definitions Reference product: registered and marketed innovative drug with demonstrated quality, safety and efficacy Generic product: similar drug to a reference or innovative drug, interchangeable, usually produced after patent expiration, with demonstrated quality, efficacy and safety, named by its DCB or DCI Similar product: contain same API, strength, dosage form, administration form, posology and indication; equivalent to registered reference drug; may be different only regarding shape and size, shelf life, packaging, labeling, excipients; always named by brand or trade mark
11 Drug Registration Rationale Pre Registration Registration Post Market RDC 136/03: Innovative Product Registration RDC 55/10: Biologic Product Registration Clinical Trial requirement RDC 16/07: Generic Product Registration RDC 17/07: Similar Product Registration Equivalence Test requirement RDC 24/11: RDC 14/10: RDC 135/03: Specific Drug Registration Herb Drug Registration Homeopathic Drug Registration 11
12 Registration Flow - Pre Submission 1) Brazilian Reference Drug or CT protocol approval - website list or request to ANVISA similar/generic only - clinical trial protocol approval innovative/biologic only 2) Samples and Manufacturing Dossier - pivotal batch or imported samples + technical documents - reference drugs: acquired in Brazil by authorized labs or CROs 3) Testing prior to Registration Submission - equivalence: QC specifications + DP (solids) similar/generic only - accelerated stability study - long term stability study: zone IV b - bioequivalence study: absorbed drugs similar/generic only - QC test (waiver for biologic drugs/transportation validation) + R&D - clinical trial results innovative/biologic only
13 Stability Study Applicable Regulation: RE 01/05 (Stability Study) similar to ICH zone IVb In vitro test: specification must be maintained during shelf life under normal storage conditions. Performed only to test drug and prior to bioequivalence test; Samples under controlled temperature and RH conditions, periodic test: accelerated: 0, 3, 6 months; long term: 0, 3, 6, 9, 12, 18, 24 months (+ every 12 months); post market: every 12 months; Specification: aspect, assay, related substances, ph (if applicable), dissolution (if applicable). Other specifications on 0 and end point; 3 batches required for registration: > 10% industrial size; Performed for higher and lower strength (proportional formulation); Performed for all primary package materials and all storage conditions; Protocol and report must be attached to the registration dossier.
14 Stability Study Study Temperature/RH Period Analysis period accelerated room temp 40 ± 2 C / 75 ± 5% 6 months 0, 3, 6 months 40 ± 2 C / 25 ± 5%* long term room temp 30 ± 2 C / 75 ± 5% 30 ± 2 C / 35 ± 5%* 6 months 0, 3, 6, 9,12, 18, 24 (+ every 12) months accelerated cold chain 25 ± 2 C / 60 ± 5% 6 months 0, 3, 6 months long term cold chain 5 ± 3 C 6 months 0, 3, 6, 9,12, 18, 24 (+ every 12) months long term freezing - 20 ± 5 C 12 months 0, 3, 6, 9,12, 18, 24 (+ every 12) months Notes: 1) Stability test is allowed at 25 C only for hospital drugs that cannot bear zone IVb conditions + chain validation 2) Impermeable packages such as glass can adopt room humidity * Semi-permeable packages
15 Registration Flow - Submission 4) Registration dossier assembly: legal, technical, testing 5) Submission to ANVISA: dossier (hard copy and CD) + fee 6) Dossier evaluation by ANVISA: 12 to 24 months (questions) 7) Registration grant: Official Gazette 8) Price Submission: innovative, biologic, generic and similar 9) Price Approval: innovative, biologic and similar only 10) Product Launch 11) Registration variation: if applicable 12) Registration renewal: every 5 years
16 Registration Flow Innovative/ biologic similar/ generic submission Protocol Approval Reference election Stability study Register Dossier Review Clinical Trial Pivotal Batch Notification CQ Test registration certificate Price Equivalence /Biostudy Register Dossier price approval 16
17 Registration Dossier for Innovative Drugs Forms, fees and legal documents: site license (QC laboratory + warehouse at least) QP certificate power of attorney third part contracts (pre-approved by ANVISA) GMP certificate issued by ANVISA & origin country HA (legalized) CPP or register evidence issued by origin country HA (legalized) Labeling lay out and leaflet model BSE data DMF: API characteristics and manufacturer information methods, specification, validation, stability synthesis route, intermediary products, contaminants, solvents polymorphic and stereoisomer data, if applicable 17
18 Registration Dossier for Innovative Drugs Product information Formula, dosage form, strengths, presentations pharmacokinetics: pka, ½ life, absorption, distribution, biotransformation, clearance indication, use, administration, posology warnings, precautions, contra indications, AE action mechanism, overdose, interactions marketing category & restrictions, batch SOP Technical information R&D report QC methods & specification + reference (API, excipient, product, packaging) CofA API and product (local and imported) stability, shelf life, storage & transport condition manufacturing process, in process control, equipment list, batch size method validation if non-pharmacopoeial 18
19 Registration Dossier for Innovative Drugs Clinical information: Pre-clinical report: toxicity (acute, sub acute, chronic, reproductive), mutagenesis, oncogenesis Clinical trial report: phase I, II and III Bioavailability report for association PSUR, pharmacovigilance plan Price Report Clinical Trial: approved by ANVISA prior to execution (if in Brazil) Patents: approved by ANVISA prior to INPI Price: approved by CMED prior to launch 19
20 QC Test: local CofA Applicable Regulations: RDC 10/11 (Imported products) RDC 16/07 (Generic Drug Registration) RDC 17/07 (Similar Drug Registration) In vitro QC test: product under registration complies with its specification; Performed at company s local QC laboratory (Brazil); All specified tests must be performed and comply with specification; Methods: according to manufacturer or justification; 20
21 QC Test: local CoA QA must release each batch after document review (including QC tests); Third party analysis: - allowed only for complex equipment or method, - allowed only for some tests, not all for the same product, - third part contract must be submitted for ANVISA's approval; CoA must be attached to registration dossier. 21
22 Generic x Similar: What s different? Generic (Res. RDC 16/07) - equivalent to a reference (API, strength, dosage form, administration, posology, indication of use) - interchangeable - no brand (DCB or DCI) - image ID on box - price 65% below reference - restriction for OTC registration Similar (Res. RDC 17/07) - equivalent to a reference (API, strength, dosage form, administration, posology, indication of use) - not interchangeable - brand - no image ID on box - price approved by ANVISA - no restriction for OTC registration With bioequivalence since 1999 No bioequivalence until
23 Similar product: Distortion x Adaptation 2013 Similar Similar Generic Innovative w/ BE RDC 133/03 w/ BE w/ BE w/ CT RDC 134/ no BE Adapting from 2004 to
24 Registration Dossier Similar/Generic Products Forms, fees and legal documents: site license (QC laboratory + warehouse at least) QP certificate power of attorney third part contracts (pre-approved by ANVISA) GMP certificate issued by ANVISA & country of origin HA (legalized) CPP or register evidence issued by country of origin HA (legalized) Labeling lay out and leaflet model BSE data DMF: API characteristics and manufacturer information methods, specification, validation route of synthesis, intermediary products, contaminants, solvents polymorphic and stereoisomer data, if applicable 24
25 Registration Dossier Similar/Generic Products Product information Formula, dosage form, strengths, presentations indication, use, administration, posology warnings, precautions, contra indications, AE action mechanism, overdose, interactions marketing category & restrictions, batch SOP Technical information R&D report QC methods & specification + reference (API, excipient, product, packaging) CofA API and product (local and imported) stability, shelf life, storage & transport condition manufacturing process, in process control, equipment list, batch size 3 batch records: < 3 years, higher & lower strength, used on equivalence test method validation if non-pharmacopoeial 25
26 Registration Dossier Similar/Generic Products Clinical information: pharmaceutical equivalence certificate bioequivalence study, if applicable Price also regulated, submitted after registration approval Pricing rules are not the same for generic, similar and innovative 26
27 Products Not Allowed as Generic Exempted from registration Parenteral drugs Biologic drugs Biotech products Vitamins and minerals Herb drugs Hospital antiseptics Radiologic contrasts and diagnostic products OTC, except: - antacids and carminatives; - non-narcotic analgesics; - non-steroidal topical anti-inflammatory, naproxen, ibuprofen, ketoprofen; - expectorants, balsamic and mucolytic agents, anti-cough; - topical antifungal; - miorelaxant products; - oral and topic anthelmintic mebendazole and levamizole; - anti-histaminic; - anti-spasmodic; - topical anti-bacterial neomycin and bacitracin; - topical hemorroidal; - topical nasal decongestant; 27
28 Pharmaceutical Equivalence Test RE 31/10 (Pharmaceutical Equivalence and Dissolution Profile Test) In vitro test: both reference and test drug contains same API, dosage, form, dissolution profile and same specifications; Performed by ANVISA s certified labs (REBLAS): acquires reference; Test drug is provided by company: pivotal batch or license to import (acquired by certified labs if product is already on the market); Prior to bioequivalence test, same batch; Pharmacopoeia methods or in-company method (full validation); All strengths must be tested; Reference and test drug results must be comparable; Pharmaceutical equivalence certificate on registration dossier. 28
29 Bioequivalence Study: Exemption Applicable Regulation: RE 37/11 (Exemption for Bioequivalence Study) Target: excludes non-absorbed products from biostudy and provides alternatives for special situations Which ones are exempted from biostudy? aqueous IM/EV drugs; aqueous solution oral drugs; powder for reconstitution; gaseous products; otological and ophthalmic solution; topical non systemic absorption products; aqueous inhalation products; non-absorbed oral products. Note: Excipients may affect absorption same as reference Ex: sorbitol When does equivalence/dissolution profile replace biostudy? Other strengths, proportional formulation (dissolution profile). Highly soluble immediate release oral forms (dissolution profile + fast dissolution results + candidate list IN 04/11). Note: Ibuprofen (biostudy) and other registered OTC (according to RE 37/11): first renewal after 30/06/12 When does pharmacodynamic study replace biostudy? otological and ophthalmic suspension inhalation products on suspension or powder (if < LOQ on plasma) 29
30 Bio exemption IN 04/2011 I - acetyl salicylic acid; II - propranolol, HCl; III - doxycycline, HCl; IV - dypirone; V - stavudine; VI - fluconazole; VII - isoniazide; VIII - levofloxacin; IX - metoprolol; X - metronidazole; XI - acetaminophen; XII - sotalol.
31 Bioequivalence Study Applicable Regulation: RE 1170/06 (Bioequivalence Study) In vivo test: both reference and test drug are equal for bioavailability on human body, considering drug amount and speed of absorption; Performed at CRO certified by ANVISA: annual inspection, acquires reference drug; Drug is provided by company: pivotal batch or license to import (acquired by certified labs if product already on market); After pharmaceutical equivalence test (same batch), stability test and Ethics Committee approval for protocol. Test and reference drug assay variation < 5%, meet all specifications; Usually higher strength of absorbed product requires biostudy (linear pharmacokinetic and non-linear pharmacokinetic when higher dose causes disproportional higher increase of pharmacokinetic parameters); lower strength (higher dose causes disproportional lower increase of pharmacokinetic parameters); Clinical, analytical and statistical phases; Biostudy protocol and report on registration dossier. 31
32 Registration Variation Applicable Regulation: RDC 48/09 + IN 11/09 Immediate Marketing: - packaging site: change or inclusion (primary/secondary) - manufacturing process: minor change - equipment: change or inclusion (packaging/mfg same design) - batch size: inclusion up to 10 times registered one - excipient: minor change - methods/specifications: authorized pharmacopoeia/ < limit - manufacturing /packaging site exclusion - shelf life reduction: same storage conditions Marketing after 60 days: - manufacturing site: change or inclusion (mfg process, none or minor changes and/or equipment having same design) Note: Annual review must include those changes (submission) 32
33 Registration Variation Marketing After Approval: manufacturing process: minor or major change equipment: change/inclusion mfg equipment different design batch size: inclusion above 10 times registered one new presentation: flavor addition excipient: minor or major change methods & specifications update: other pharmacopoeias, change/exclusion shelf life and/or storage condition change presentation inclusion packaging inclusion route of synthesis change or inclusion API manufacturer change or inclusion posology change target population inclusion administration via inclusion: innovative or non-innovative indication of use inclusion: innovative or non-innovative new strength inclusion: innovative or non-innovative new dosage form inclusion: innovative or non-innovative labeling change: not related to other changes trade mark change manufacturing interruption/ reactivation registration cancellation: full or partial 33
34 Registration Renewal Submission: - Every 5 years - Filed 6 months before registration expiration date - Automatic renewal by law Note: ANVISA may monitor quality of batches on market. long term stability study final report Legal documents, forms and fees Commercialization evidence Leaflet Modification list CofA for 3 batches (imported only) GMP PSUR Phase IV report (not mandatory) 34
35 Biologic Drugs This extensive topic will be the subject of another webcast. Applicable Regulation: RDC 55/10 Biologic drugs - biological origin or biotechnology for mfg: Vaccine Serum Blood compounds Bio drugs: from biologic fluids or animal tissue from biotechnology Monoclonal antibody Drug with microorganisms (alive, dead or attenuated) Does not include antibiotics, estrogens (contraceptives), allergenic, probiotic There is no definition for biosimilar, only for biologic drugs (innovative and non innovative). Possibilities: comparability or development 35
36 OTC Applicable Regulation: RDC 138/03 (GITE Specific Therapeutic Groups and Indications) New molecule must be registered as innovative even if indication/therapeutic group is listed on GITE GITE lists all indications/therapeutic groups that are prescription free Any product registered more than 5 years in FDA or EMEA as OTC plus PSUR (safety) may receive approval as OTC in Brazil 36
37 Timelines Step Legal Actual Inspection 120 days 1 year Registration Innovative 90 days 2 years Registration Similar 120 days 19 months Registration Priority 60 days 1 year Price Approval 60 days 60 days ANVISA Questions: days to answer at most; OR archive up to 360 days. 37
38 Q & A Thank You! Adriana Serrão & Marcela Saad Regulatory Affairs President & Senior Consultant serraoguilherme@uol.com.br MarcM Consulting Canada saadma@marcmconsulting.ca
1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country
1. Checklist for Grant of permission to manufacture/import of Bulk Drug already approved in the country S no 1. Name of Applicant with address 2. Name of Drug 3. Therapeutic Class 4. Date of Approval Documents
More informationOfficial Letter from the DOH
Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please
More informationGUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs)
GUIDANCE FOR INDUSTRY ON FIXED DOSE COMBINATIONS (FDCs) DRAFT GUIDANCE This guidance document is for feedback purposes only Comments and suggestions regarding this draft document should be submitted within
More informationA GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Finished Pharmaceutical Product Questionnaire This questionnaire is used to collect information from vendors with regards to finished pharmaceutical products
More information1. Patentable Subject Matter in the Pharmaceutical Sector
540 CHAPTER 23 1. The provision of marketing literature and/or advertising material; 2. The provision of demonstration articles; 3. The provision of sales training to the subsidiary s staff; 4. Involvement
More informationDecentralised Procedure. Public Assessment Report
Decentralised Procedure Public Assessment Report Aspirin Complex Hot drink 500 mg / 30 mg granules for oral suspension Acetylsalicylic acid / pseudoephedrine DE/H/3635/001/DC Applicant: Bayer Vital GmbH
More informationICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
European Medicines Agency August 2003 CPMP/ICH/4680/02 ICH Topic M 4 Q Location issues for Common Technical Document for the Registration of Pharmaceuticals for Human Use Quality Questions and Answers
More informationWHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products
WHO GUIDELINE Stability testing of active pharmaceutical ingredients and finished pharmaceutical products 1. Introduction 1.1 Objectives of these guidelines 1.2 Scope of these guidelines 1.3 General principles
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationINFORMATION ON JAPANESE REGULATORY AFFAIRS
2017 INFORMATION ON JAPANESE REGULATORY AFFAIRS Regulatory Information Task Force Japan Pharmaceutical Manufacturers Association Pharmaceutical Administration and Regulations in Japan Japan Pharmaceutical
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationRepublic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a
Republic of the Philippines Department of Health OFFICE OF THE SECRETARY M a n i l a March 15, 1989 ADMINISTRATIVE ORDER No. 67 s. 1989 SUBJECT: Revised Rules and Regulations on Registration of Pharmaceutical
More informationCTA/NDA Regulatory Landscape in China. Jack Xie, PhD, DABT SOT 2016
CTA/NDA Regulatory Landscape in China Jack Xie, PhD, DABT SOT 2016 Disclaimer The content of the following presentation represents solely author s view and may not reflect any position of Roche or China
More informationThe rules governing medicinal products in the European Union. Presentation and content of the dossier Edition
The rules governing medicinal products in the European Union Volume 2B Notice to Applicants Medicinal products for human use Presentation and content of the dossier 1998 Edition EUROPEAN COMMISSION Directorate
More informationMultisource (generic) pharmaceutical products: guidelines on registration requirements to establish
Annex 7 Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability 1 1. Introduction 134 2. Glossary 135 3. Documentation of equivalence for
More informationFDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS
FDA S GUIDANCE FOR INDUSTRY ANDAS: STABILITY TESTING OF DRUG SUBSTANCES AND PRODUCTS 02-December-2014 San Diego, CA Kim Huynh-Ba Executive Director PHARMALYTIK Kim.huynhba@pharmalytik.com Overview Stability
More informationFormulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza
Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation
More informationKFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar
KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical
More informationGUIDELINE FOR THE STABILITY TESTING
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 GUIDELINE FOR THE STABILITY TESTING OF NON-PRESCRIPTION (OTC)
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationPublic Assessment Report. Scientific discussion. Naproxennatrium Banner 220 mg capsules, soft (naproxen sodium) NL/H/2804/001/DC. Date: 28 April 2014
Public Assessment Report Scientific discussion Naproxennatrium Banner 220 mg capsules, soft (naproxen sodium) NL/H/2804/001/DC Date: 28 April 2014 This module reflects the scientific discussion for the
More informationBEAM ASPECTS OF COMPOUNDING PRODUCT DESIGN. Reinout C.A. Schellekens, PharmD, RHPh, QP. Head Clinical Drug Production and Development
- ASPECTS OF COMPOUNDING PRODUCT DESIGN Reinout C.A. Schellekens, PharmD, RHPh, QP Head Clinical Drug Production and Development Department of Hospital and Clinical Pharmacy University Medical Center Groningen,
More informationIntroduction to CMC Regulatory Affairs
Introduction to CMC Regulatory Affairs Bharathi Mamidipudi Regulatory Affairs Consultant II Syner-G Pharma Consulting, LLC Northeastern University, Boston November 10, 2016 My Background Experience ~4
More informationAppropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products
Date: April 23, 2012 Appropriate Control Strategies Eliminate the Need for Redundant Testing of Pharmaceutical Products Key Messages Importation quality control testing for pharmaceutical, biological/biotechnology
More informationPublic Assessment Report. Scientific discussion. Kruidvat Paracetamol liquid caps 500 mg, soft capsules. (paracetamol) NL License RVG:
Public Assessment Report Scientific discussion Kruidvat Paracetamol liquid caps 500 mg, soft capsules (paracetamol) NL License RVG: 116359 Date: 10 April 2017 This module reflects the scientific discussion
More informationZAMBIA MEDICINES REGULATORY AUTHORITY APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINE FOR HUMAN USE
ZAMBIA MEDICINES REGULATORY AUTHORITY APPLICATION FOR MARKETING AUTHORISATION OF A MEDICINE FOR HUMAN USE GUIDANCE FOR THE PREPARATION AND SUBMISSION OF DOSSIERS IN COMMON TECHNICAL DOCUMENT FORMAT Version
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationDraft regional guidelines on stability testing of active substances and pharmaceutical products
Regional Committee for the EM/RC53/12 Eastern Mediterranean August 2006 Fifty-third Session Original: Arabic Agenda item 17 Draft regional guidelines on stability testing of active substances and pharmaceutical
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE:
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit - FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE: DEVELOPMENT PHARMACEUTICS FOR VETERINARY
More informationGlossary of Abbreviations
Glossary of Abbreviations ANDA APhA Abbreviated New Drug Application American Pharmaceutical Association API Active Pharmaceutical Ingredient BA/BE Bioavailability/Bioequivalence BE Bioequivalence Bio
More informationBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies Standard Approach Part I: Design and Conduct H. Rettig, Ph.D. LLC www.ivivc.com Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98
More informationNew TB Drugs Approval in Thailand
New TB Drugs Approval in Thailand Tharnkamol Chanprapaph,, Ph.D. Drug Control Division, Thai Food and Drug Administration Third Annual Open Forum on Key Issues in Tuberculosis Drug Development, New Delhi,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More information"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY
"NOT FOR IMPLEMENTATION" GUIDANCE FOR INDUSTRY Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo
More informationWHO GENERAL GUIDANCE ON VARIATIONS TO MULTISOURCE PHARMACEUTICAL PRODUCTS. (February 2014)
February 2014 Draft for comment 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 World Health Organization 2014 All rights reserved.
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products. Proposed guidelines
0 0 0 0 WHO/PAC for BTPs_DRAFT/ Oct 0 ENGLISH ONLY Guidelines on procedures and data requirements for changes to approved biotherapeutic products Proposed guidelines NOTE: This document has been prepared
More informationFlexible and Pending Monographs
Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention Flexible Monographs: Background From
More informationSalient Features of IP-2010 (VI edition)
Salient Features of IP-2010 (VI edition) By:- Dr. Raman Mohan Singh Principal Scientific Officer, IPC-IPL, IPL, Ghaziabad. Website: www.ipc.gov.in Email: ipclab@vsnl.net As per the Drugs and Cosmetics
More informationDerivation and Justification of Safety Thresholds
Derivation and Justification of Safety Thresholds Douglas J. Ball, MS, DABT Chair, PQRI L&E Toxicology Subgroup Research Fellow, Safety Sciences - Pfizer, Inc. Agenda Basic Definitions Current Regulatory
More informationCERTIFICATE IN BIOPHARMACEUTICALS
Temple University - School of Pharmacy 425 Commerce Drive, Suite 175 Fort Washington, PA 19034-2713 Phone: 267.468.8560 Fax: 267.468.8565 CERTIFICATE IN BIOPHARMACEUTICALS and GENERIC DRUGS Temple offers
More informationPublic Assessment Report. Scientific discussion. Pregamid 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg hard capsules.
Public Assessment Report Scientific discussion Pregamid 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg hard capsules (pregabalin) NL/H/3245/001-008/DC Date: 27 July 2016 This module reflects
More informationPre-Screening revised checklist for BA/BE NOC for Export Purpose
Pre-Screening revised checklist for BA/BE NOC for Export Purpose O/o Drugs Controller General (India) Directorate General of Health Services FDA Bhawan, New Delhi (With effective from 25 th April 2014)
More informationSeite 1 von 13 (February 18, 1997) All NDA, ANDA, and AADA Holders Dear Sponsors: On November 30, 1995, the Scale-up and Post-Approval Changes Guidance for Immediate Release Products (SUPAC-IR) was published.
More informationto The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government No. 29.
STATUTORY INSTRUMENTS SUPPLEMENT No. 8 28th March, 2014 STATUTORY INSTRUMENTS SUPPLEMENT to The Uganda Gazette No. 18 Volume CVII dated 28th March, 2014 Printed by UPPC, Entebbe, by Order of the Government.
More informationDirector of Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
Provisional translation (as of March 27, 2008) 1 PFSB / ELD Notification No. 0210004 February 10, 2005 *Revised in accordance with PFSB / ELD Notification No. 0619004 June 19, 2007 Director of Evaluation
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationI. DEFINITION This training under Kilimanjaro School of Pharmacy Industrial Pharmacy Teaching Unit (IPTU) is an Advanced Training Program in Drug Development, Drug Manufacturing, Regulatory & Quality Compliance.
More informationPHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS
RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationPublic Assessment Report. Scientific discussion. Lacidipine Double-e Pharma 2 mg, 4 mg and 6 mg film-coated tablets. (lacidipine)
Public Assessment Report Scientific discussion Lacidipine Double-e Pharma 2 mg, 4 mg and 6 mg film-coated tablets (lacidipine) NL/H/2992/001-003/DC Date: 28 July 2016 This module reflects the scientific
More informationREGULATION OF BIOLOGICAL PRODUCTS IN PERU. Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID)
REGULATION OF BIOLOGICAL PRODUCTS IN PERU Vicky Roxana Flores Valenzuela General Directorate of Medicines, Supplies and Drugs (DIGEMID) CONTENTS Introduction of DIGEMID Legal Bases of Biological Products
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationOVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS IN EMERGING MARKET
Badjatya et al Journal of Drug Delivery & Therapeutics; 2013, 3(2), 227-232 227 Available online at http://jddtonline.info REVIEW ARTICLE OVERVIEW OF DRUG REGISTRATION REQUIREMENTS FOR PHARMACEUTICALS
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationRegulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products.
Regulatory perspectives on CQAs, CPPs, and Risk Analyses for Combination Products. 3rd FDA/PQRI Conference on Advancing Product Quality March 22-24, 2017 TRACK #2 Achieving Drug Product Quality: Novel
More informationPharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148
Request for Proposal Pharmaceutical Development (Drug Substance & Drug Product) for Visceral Leishmaniasis candidate DNDI-6148 Dated: October 12 th 2015 Page 1 Table of Contents 1. PURPOSE... 3 2. RFP
More informationGLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE
GLOBAL HEALTH SUPPLY CHAIN QUALITY ASSURANCE Medical Device Product Questionnaire This questionnaire is used to collect information from vendors with regards to medical devices that fall in any of the
More informationNew Zealand Regulatory Guidelines for Medicines
New Zealand Regulatory Guidelines for Medicines Part C: Requirements for application types Edition 6.16 September 2014 (consolidation of fifth edition and subsequent updates) Table of Contents PART C:
More informationRecent FDA Guidance For Industry; BCS Class 1 and 3 August 2015
Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015 Bryan Crist Scientific Affairs Manager, Agilent Technologies, Dissolution Systems Dissolution Exchange WebEx Bryan.crist@agilent.com August,
More informationReflection Paper. The Role of Product-specific Monographs for Biotherapeutic Products in Pharmacopoeias
Reflection Paper 3 October 2014 The Role of Product-specific Monographs for Biotherapeutic Products in Pharmacopoeias This reflection paper describes a scientific and regulatory rationale for a new format
More informationGuidelines on procedures and data requirements for changes to approved biotherapeutic products
ENGLISH ONLY EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva, 17 to 20 October 2017 Guidelines on procedures and data requirements for changes to approved biotherapeutic products World Health Organization
More informationManagement Team. Over 35 years experience in the pharmaceuticals industry
2017 1 Overview Located in Bangalore, a Dedicated cgmp and cglp Compliance Laboratory Established in September 2010 Approved Contract research Organization by India FDA Approved by Health Canada since
More informationKINGSMANN CARE GROUP
PHARMA CONSULTANTS KINGSMANN CARE GROUP KINGSMANN CONSULTANCY SERVICES Thank you for taking interest in Kingsmann Consultancy Services. Kingsmann Consultancy (KC) is a leading business development-consulting
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More informationThe Children s Hospital of Philadelphia Committees for the Protection of Human Subjects Policies and Procedures Determination of IND/IDE Requirement
Page: 1 of 8 I. PURPOSE II. III. IV. The purpose of this Standard Operating Procedure is to delineate when an investigator must obtain an Investigational New Drug (IND) or Investigational Device Exemption
More informationManual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trial Specific Dossier v.1
Manual for Submission of Drug Clinical Development Dossier (DCDD) and Clinical Trial Specific Dossier v.1 Brasília, 2015 Copyright 2015. Brazilian Health Surveillance Agency. Partial or complete reproduction
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationInvestigator-Initiated INDs
Investigator-Initiated INDs Marjorie Small, RN, CCRC Office of Clinical Research 23 May 2011 PPHS/IRB Research Grand Rounds Outline of Presentation I. What is an IND? II. Code of Federal Regulations III.
More informationCancer Vanguard. Biosimilars Trust Policy Template
Cancer Vanguard Biosimilars Trust Policy Template Aim of this document: The document provides generic guidance and outline for the development of local trust policies in relation to the adoption of biosimilars
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationGUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA
GUIDELINES ON THE STABILITY DATA REQUIRED FOR REGISTRATION OF STOCK REMEDIES IN SOUTH AFRICA Issued by the Registrar: Act No. 36 of 1947, Private Bag X343, Pretoria 0001 Republic of South Africa Tel. (**27
More informationGUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER
RESTRICTED GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER Since being presented to the Fortieth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2005 this
More informationJ Pharm Pharmaceut Sci (www.cspscanada.org) 12(2): , 2009
Where is Industry Getting it Wrong? A Review of Quality Concerns Raised at Day 120 by the Committee for Medicinal Products for Human Use during European Centralised Marketing Authorisation Submissions
More informationGUIDELINES FOR SUBMISION OF POST- APPROVAL VARIATION MEDICINE APPLICATIONS
GUIDELINES FOR SUBMISION OF POST- APPROVAL VARIATION MEDICINE APPLICATIONS FOOD, MEDICINE AND HEALTH CARE ADMINSTRATION AND CONTROL AUTHORITY OF ETHIOPIA (EFMHACA) First Edition December, 2015 Table of
More informationGood Procurement Practices for artemisinin-based antimalarial medicines
Good Procurement Practices for artemisinin-based antimalarial medicines AMDS Partners and Stakeholders Meeting Geneva, 23 March 2010 Silvia Schwarte Medicines and Diagnostics Unit Global Malaria Programme
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationAPPLICATION FOR VARIATION TO A MARKETING AUTHORISATION
Page 1 of 13 May 2008 APPLICATION FOR VARIATION TO A MARKETING AUTHORISATION HUMAN VETERINARY NATIONAL AUTHORISATION IN MRP MRP variation number 1A : / / / / / COMMUNITY AUTHORISATION EMEA variation number
More informationHosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil)
Hosting Inspections from foreign countries: PMDA (Japan) ANVISA (Brazil) Kathrin Abelein Vice President Quality, R-Pharm, JSC First Russian GMP Conference 20. 22. September 2016 Agenda General information
More informationDr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority
CHALLENGES AND OPPORTUNITIES IN COLD CHAIN: HEALTH CARE RELATED DRIVERS Dr. Abdulrahman Mohammad Al Jassmi Chief Executive Officer Dubai Hospital Dubai Health Authority AGENDA Integrating stakeholders
More informationA.1 Contents file 4 to 5 A.1 (1)
Contents file 4 to 5 Contents file 4 to 5 A Information Contents file 4 to 5 A.2 Index file 4 to 5 A.3 List of Abbreviations A.4 Glossary A.5 Adress-Register A.6 References B Japanese Regulations B.1 MHW
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION
Reprinted from FDA s website by EAS Consulting Group, LLC ANDA FILING CHECKLIST (CTD or ectd FORMAT) FOR COMPLETENESS AND ACCEPTABILITY of an APPLICATION ANDA: APPLICANT: RELATED APPLICATION(S): DRUG NAME:
More informationReflection paper on the dissolution specification for generic solid oral immediate release products with systemic action
10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper
More informationEUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL QUESTIONS. and ANSWERS
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Consumer goods Pharmaceuticals Brussels, F2/SM D (2008) QUESTIONS and ANSWERS The rules governing medicinal products in the European Union VOLUME 2 NOTICE
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More informationJustification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery
Justification of Specifications (JOS): What Product and Process Development was all About Christopher A Bravery cbravery@advbiols.com 1 The Importance of Characterisation 2 http://www.advbiols.com/documents/importance
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management
ICH Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Keith O. Webber, Ph.D. Sr. Director, Global Regulator Affairs Rx Perrigo Company, plc Q U A L I T Y A F F
More informationICH, WHO AND SUPAC GUIDELINES
ICH, WHO AND SUPAC INTRODUCTION: GUIDELINES ICH GUIDELINES The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) is a unique project
More informationPreclinical Drug Development
Preclinical Drug Development A guidance prepared by From a 2004 NIH Summit Workshop: A major reason for the tremendous cost of drug development is the high rate of drug candidate failure during clinical
More informationPPB Guideline to submission Page 1 of 94
REPUBLIC OF KENYA REGISTRATION OF DRUGS GUIDELINES TO SUBMISSION OF APPLICATIONS PHARMACY AND POISONS BOARD PPB Copyright 2010 PPB Guideline to submission Page 1 of 94 ACKNOWLEDGEMENTS The following persons
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationWorkshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing
Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Session 7: National regulatory authority s role in product commercialization, licensing and innovation of influenza vaccines
More informationQuality Assurance of Medicines Terminology Database - List of Terms and related guideline
Accelerated (stress) stability studies Stability of drug dosage forms (Annex 1, 31st report, 1990) Studies designed to increase the rate of chemical or physical degradation of a drug by using degradation
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More information